Galectin Therapeutics
Stock Forecast, Prediction & Price Target
Galectin Therapeutics Financial Estimates
Galectin Therapeutics Revenue Estimates
Galectin Therapeutics EBITDA Estimates
Galectin Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $36.32M Low: $36.32M High: $36.32M avg. 0% | Avg: $179.68M Low: $179.68M High: $179.68M avg. 394.73% | Avg: $385.24M Low: $385.24M High: $385.24M avg. 114.39% | Avg: $572.21M Low: $572.21M High: $572.21M avg. 48.53% |
Net Income
% change YoY
| $-30.97M N/A | $-39.2M -26.55% | $-41.06M -4.76% | Avg: $-95.65M Low: $-95.65M High: $-95.65M avg. -132.92% | Avg: $-58.35M Low: $-58.35M High: $-58.35M avg. 38.99% | Avg: $79.40M Low: $79.40M High: $79.40M avg. 236.08% | Avg: $206.34M Low: $206.34M High: $206.34M avg. 159.84% |
EBITDA
% change YoY
| $-30.17M N/A | $-38.3M -26.92% | $-202K 99.47% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.53 N/A | -$0.66 -24.52% | -$0.74 -12.12% | Avg: -$1.59 Low: -$1.59 High: -$1.59 avg. -114.86% | Avg: -$0.97 Low: -$0.97 High: -$0.97 avg. 38.99% | Avg: $1.32 Low: $1.32 High: $1.32 avg. 236.08% | Avg: $3.43 Low: $3.43 High: $3.43 avg. 159.84% |
Operating Expenses
% change YoY
| $30.17M N/A | $38.35M 27.08% | $38.07M -0.73% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Galectin Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 75.50% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -95.65M, average is -95.65M and high is -95.65M.
What is Galectin Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 139.41% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $36.32M, average is $36.32M and high is $36.32M.
What is Galectin Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 80.01% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.59, average is -$1.59 and high is $-1.59.